Serum Sickness in a Multiple Sclerosis Patient Treated with Ocrelizumab

Overview

Journal J Neurol

Specialty Neurology

Date 2023 Nov 1

PMID 37907726

Authors

Vittorio Mantero

Christian Cordano

Roberto Balgera

Paola Basilico

Giovanni Novi

Andrea Salmaggi

Affiliations

Soon will be listed here.

References

Karmacharya P, Poudel D, Pathak R, Donato A, Ghimire S, Giri S . Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheum. 2015; 45(3):334-40. DOI: 10.1016/j.semarthrit.2015.06.014. View

Moreira Ferreira V, Kimbrough D, Stankiewicz J . A possible case of serum sickness after ocrelizumab infusion. Mult Scler. 2020; 27(1):155-158. DOI: 10.1177/1352458520910486. View

Rjeily N, Nourbakhsh B, Mowry E . Serum Sickness/Serum Sickness-like Reactions Following Ocrelizumab Infusion in 2 Patients With Multiple Sclerosis. Int J MS Care. 2023; 25(5):196-198. PMC: 10503817. DOI: 10.7224/1537-2073.2022-080. View

Kumar A, Khamkar K, Gopal H . Serum sickness and severe angioedema following rituximab therapy in RA. Int J Rheum Dis. 2012; 15(1):e6-7. DOI: 10.1111/j.1756-185X.2011.01645.x. View

Bayer G, Agier M, Lioger B, Lepelley M, Zenut M, Lanoue M . Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. Eur J Intern Med. 2019; 67:59-64. DOI: 10.1016/j.ejim.2019.06.009. View

Holmoy T, Fogdell-Hahn A, Svenningsson A . Serum sickness following rituximab therapy in multiple sclerosis. Neurol Clin Pract. 2020; 9(6):519-521. PMC: 6927430. DOI: 10.1212/CPJ.0000000000000685. View

Wolf A, Zhovtis Ryerson L, Pandey K, McGettigan B, Vollmer T, Corboy J . Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019; 36:101402. DOI: 10.1016/j.msard.2019.101402. View

Krumbholz M, Pellkofer H, Gold R, Hoffmann L, Hohlfeld R, Kumpfel T . Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007; 64(9):1331-3. DOI: 10.1001/archneur.64.9.1331. View

Lapucci C, Gualandi F, Mikulska M, Palmeri S, Mancardi G, Uccelli A . Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report. Mult Scler Relat Disord. 2018; 26:52-54. DOI: 10.1016/j.msard.2018.09.006. View

10.

Saba J, Logan A . Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia. Clin Case Rep. 2017; 5(6):891-893. PMC: 5457998. DOI: 10.1002/ccr3.969. View

11.

Elmanaseer O, Avelino A, Azem A, Raval M . Serum sickness reaction to obinutuzumab in a patient with chronic lymphocytic leukaemia. BMJ Case Rep. 2021; 14(12). PMC: 8704971. DOI: 10.1136/bcr-2021-245557. View

12.

Joubert M, Paris P, Clavelou P, Moisset X . Ocrelizumab can be used in multiple sclerosis after a rituximab-induced serum sickness: A case report. Rev Neurol (Paris). 2021; 177(8):1041-1042. DOI: 10.1016/j.neurol.2020.11.003. View

13.

Doyle A, Stubbs M, Lester W, Thomas W, Westwood J, Thomas M . The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura. Br J Haematol. 2022; 198(2):391-396. DOI: 10.1111/bjh.18192. View

14.

Rapp M, Pentland A, Richardson C . Successful Treatment of Pemphigus Vulgaris With Ofatumumab. J Drugs Dermatol. 2018; 17(12):1338-1339. View

15.

Al-Araji S, Ciccarelli O . A possible case of serum sickness after ocrelizumab infusion - Commentary. Mult Scler. 2020; 27(1):158-159. DOI: 10.1177/1352458520923947. View